NVP BHG 712
Discontinued ProductNVP BHG 712 (Cat. No. 4405) has been withdrawn from sale for commercial reasons.
Selective inhibitor of EphB4 kinase; exhibits selectivity for EphB4 over more than 40 other kinases in vitro, including FGFR3. Inhibits EphB4 autophosphorylation in transiently transfected HEK 293 cells. Also inhibits VEGF-induced angiogenesis in vivo; thought to inhibit EphB4 forward signaling. Orally active.
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
References are publications that support the biological activity of the product.
Martiny-Baron et al (2010) The small molecule specific EphB4 kinase inhibitor NVP-BHG712 inhibits VEGF driven angiogenesis. Angiogenesis. 13 259 PMID: 20803239
Wnuk et al (2012) Podocyte EphB4 signaling helps recovery from glomerular injury. Kidney Int. 81 1212 PMID: 22398409
View Related Products by Product Action
Keywords: NVP BHG 712, NVP BHG 712 supplier, NVPBHG712, EphB4, kinase, inhibitors, inhibits, ephrinB2, EphB2, ephrin, VEGF, angiogenesis, antiangiogenics, ephrins, Eph, Receptors, 4405, Tocris Bioscience
Citations for NVP BHG 712
Citations are publications that use Tocris products.
Currently there are no citations for NVP BHG 712.
Reviews for NVP BHG 712
There are currently no reviews for this product. Be the first to review NVP BHG 712 and earn rewards!
Have you used NVP BHG 712?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.